Hester Biosciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹98 Cr +38% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
HB

Hester Biosciences Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Hester Biosciences Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹100Cr
+22% YoY
+29.9% QoQ
Net profit
₹17Cr
+750% YoY
+88.9% QoQ
Margin
34%
+11 pp YoY
+11 pp QoQ
Price₹2,368
Market cap₹2.1K Cr
P/E38.7

The short version

The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term. Focus on strengthening Animal Health division and biologicals, expected to pick up alongside Poultry segment.

From Hester Biosciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term.
  • Poultry Healthcare showed strong growth, with sustained demand and 41% Q4 growth, indicating ongoing momentum.
  • Focus on expanding market penetration both domestically and in export markets, especially in Africa, with strategic emphasis on biologicals and vaccine portfolio strengthening.
  • Capacity expansions like Fill-Finish and BSL-3 facilities enhance product capacity and provide scalability without immediate need for new capital expenditure.

2 more points from Hester Biosciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Hester Biosciences capitalized Fill-Finish and BSL-3 facilities during the year as part of manufacturing and infrastructure expansion to enhance capacity and flexibility for domestic and export markets.
  • Optimization initiatives for BSL-3 facility are ongoing to improve utilization efficiency and operating costs aligned with current operational and scale-up needs.
  • No definitive plan to allocate further capital expenditure currently, but evolving regulatory requirements and new technologies may necessitate future investments.
  • Company aims to optimize utilization of installed capacities rather than immediately expanding further.
  • Strategic focus includes strengthening biologicals portfolio, improving capacity utilization, and expanding market penetration.

2 more points from Hester Biosciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The Animal Healthcare division faced delays in tender-led immunization programs during FY26 due to timing issues beyond the company's control.
  • Execution of tender orders started picking up from Q4 FY26 onwards.
  • Demand visibility for Animal Healthcare tender programs remains strong but dependent on country-level rollout schedules.

2 more points from Hester Biosciences Ltd's call on order book

Create a free account to keep reading this call

Hester Biosciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Hester Biosciences Ltd Q4 FY26 results — key figures

Hester Biosciences Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue10082+22%77+29.9%
Operating profit (EBITDA)3419+78.9%18+88.9%
Operating margin34%23%+11 pp23%+11 pp
Profit before tax254+525%14+78.6%
Net profit (PAT)172+750%9+88.9%
EPS (₹)18.781.52+1135.5%10.31+82.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹98 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Hester Biosciences Ltd Q4 FY26 results?

The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term. Focus on strengthening Animal Health division and biologicals, expected to pick up alongside Poultry segment.

What is Hester Biosciences Ltd share price analysis?

Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hester Biosciences Ltd planning capital expenditure?

Hester Biosciences capitalized Fill-Finish and BSL-3 facilities during the year as part of manufacturing and infrastructure expansion to enhance capacity and flexibility for domestic and export markets.

Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.